Portola Pharma Cmn (PTLA) 25.98 $PTLA
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.27 (-0.01), PTLA: 25.98 (+0.02), ANTH: 3.08 (+0.02), NERV: 11.10 (-0.11)
Corridor Company Case Study Examines Portola Pharmaceuticals' Use of Corridor's CLM Product in Managing All Aspects of Portola's Contract Management Process
PRWeb - Wed Jun 22, 2:48AM CDT
Corridor Company, Inc., the leading provider of contract lifecycle management software powered by the SharePoint and Office 365 platforms, has published a case study about the successful deployment of its Contract Management Business Application for SharePoint, CM[.app], by Portola Pharmaceuticals, a biopharmaceutical company with a foundation of products and product candidates that significantly advances patient care in the areas of thrombosis, other hematologic disorders and inflammation. Portola's legal and finance teams now use Corridor's software to manage their entire contract lifecycle, including contract creation and request, negotiation with external parties, documented approval, and metadata reporting.
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies.
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Tue May 31, 3:05PM CDT
Portola Pharmaceuticals (NasdaqTLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37 Annual Healthcare Conference on Tuesday, June 7, 2016, at 1:20 p.m. Pacific Time in Rancho Palos Verdes, Calif.
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
GlobeNewswire - Fri May 27, 7:45AM CDT
--Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016--
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa(TM) (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting
GlobeNewswire - Mon May 23, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured in an oral session at the 62nd Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH), which will take place from May 25-28 in Montpellier, France. Additionally, new data from pharmacokinetic and mechanism of action studies of the Company's Factor Xa inhibitor antidote AndexXa (andexanet alfa) will be presented in poster sessions.
PTLA: 25.98 (+0.02)
How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 25.98 (+0.02), ANTH: 3.08 (+0.02), VTAE: 10.65 (-0.40), ITCI: 40.80 (-0.17)
Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Thu May 05, 3:06PM CDT
Portola Pharmaceuticals Inc. (NASDAQTLA), today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016.
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Thu Apr 14, 7:00AM CDT
Portola Pharmaceuticals (NasdaqTLA) today announced that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans.
PTLA: 25.98 (+0.02)
3 Biotech Takeover Targets That Could Get Bought Soon
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 2:39PM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Biotech stocks have been especially hard hit over the past six months because of concerns over drug prices, and the sell-off within the industry has resulted in bargains that big pharma might find compelling. Among...
MDVN: 64.22 (+0.23), BMRN: 99.78 (+0.36), PTLA: 25.98 (+0.02), KITE: 57.00 (+0.37), AMGN: 172.20 (+0.17), BMY: 75.31 (+0.50)
What Made Portola Pharmaceuticals Shares Collapse 33% in March
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 4:02PM CDT
IMAGE SOURCE: PORTOLA PHARMACEUTICALS. What: After reporting confusing and arguably mixed results from a late-stage study, shares of Portola Pharmaceuticals lost roughly a third of their value last month, according to data from S&P...
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis (ISTH) SSC Meeting 2016 on May 27, 2016
GlobeNewswire - Wed Apr 06, 7:07AM CDT
Portola Pharmaceuticals (NasdaqTLA) today announced that data from its Phase 3 APEX Study of betrixaban will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 62nd Annual SSC (Scientific and Standardization Committee) Meeting, which is taking place from May 25-28 in Montpellier, France. Portola is developing betrixaban, an oral Factor Xa inhibitor anticoagulant, for the prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients.
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with Edoxaban in Japan
GlobeNewswire - Mon Apr 04, 7:00AM CDT
Portola Pharmaceuticals (NASDAQTLA), announced today that it has entered into a clinical collaboration agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban, Daiichi Sankyo's Factor Xa inhibitor, in Japan.
PTLA: 25.98 (+0.02)
Portola Hits 52-Week Low on Unfavorable Betrixaban Data
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 10:30AM CDT
Shares of Portola (PTLA) hit a new 52-week low on unfavorable top-line data from the phase III APEX study on betrixaban.
PTLA: 25.98 (+0.02), EBS: 33.39 (+0.54), AMAG: 26.53 (-0.06), SNY: 42.63 (+0.03)
Portola Pharma and Williams skid, Office Depot and PVH climb
AP - Thu Mar 24, 3:51PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq stock market:
SPLS: 9.29 (+0.06), PTLA: 25.98 (+0.02), TEX: 24.14 (+0.59), ODP: 3.46 (-0.05), PVH: 101.06 (+1.44)
Why Portola Pharmaceuticals Inc's Stock Is Bleeding Red Today
Brian Feroldi, The Motley Fool - Motley Fool - Thu Mar 24, 12:12PM CDT
Image source: TBIT via Pixabay. What: Shares of Portola Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies for thrombosis and other hematologic diseases, dropped by more than 22% as of 11:00 a.m. EST...
PTLA: 25.98 (+0.02), SNY: 42.63 (+0.03)
Portola Pharmaceuticals' Betrixaban Misses Mark, But All Is Not Lost
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:14AM CDT
SOURCE: PORTOLA PHARMACEUTICALS Portola Pharmaceuticals ' 7,513 person head to head study evaluating its next-generation anticoagulant betrixaban against standard of care Lovenox in the prevention of blood clots missed its endpoint in one trial...
JNJ: 125.23 (+0.77), PTLA: 25.98 (+0.02), PFE: 37.04 (+0.15), BMY: 75.31 (+0.50), SNY: 42.63 (+0.03)
Portola Pharmaceuticals to Hold Conference Call on Thursday, March 24, at 8:30 am ET
GlobeNewswire - Thu Mar 24, 3:00AM CDT
Portola Pharmaceuticals, Inc. (NasdaqTLA) announced that it will host a conference call today, Thursday, March 24, 2016, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), to provide a company update.
PTLA: 25.98 (+0.02)
3 Emerging Biotech Stocks I'm Watching Like a Hawk
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 19, 11:02AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM. Needle-moving news could soon hit for three small-cap biotech stocks. If investors aren't paying attention, they could miss out on an opportunity. Specifically, the FDA is set to decide whether to approve ...
INSY: 15.65 (+0.01), PTLA: 25.98 (+0.02), SHPG: 194.18 (+0.06), SNY: 42.63 (+0.03), FOLD: 6.72 (-0.08)
3 Biotech Stocks to Buy in March
Cheryl Swanson, Kristine Harjes, and Brian Feroldi, The Motley Fool - Motley Fool - Fri Mar 18, 3:39PM CDT
Looking for stocks to buy? It's time to get in some shots before the weather warms up. Flickr: Creative Commons March--as the saying goes--comes in like a lion and goes out like a lamb. And biotechs may be about to do the same, although it's...
PTLA: 25.98 (+0.02), IBB: 290.67 (+1.23), IONS: 38.15 (+8.96), REGN: 425.12 (+14.08)
Biotechnology Stocks in Motion -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma
PR Newswire - Wed Jun 22, 7:20AM CDT
On Tuesday, June 21, 2016, the NASDAQ Composite ended the trading session at 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% to finish at 17,829.73; and the S&P 500 closed at 2,088.90, up 0.27%. The gains were broad based as five out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by accessing their free trade alerts at:
TRVN: 6.27 (-0.01), PTLA: 25.98 (+0.02), ANTH: 3.08 (+0.02), NERV: 11.10 (-0.11)
Corridor Company Case Study Examines Portola Pharmaceuticals' Use of Corridor's CLM Product in Managing All Aspects of Portola's Contract Management Process
PRWeb - Wed Jun 22, 2:48AM CDT
Corridor Company, Inc., the leading provider of contract lifecycle management software powered by the SharePoint and Office 365 platforms, has published a case study about the successful deployment of its Contract Management Business Application for SharePoint, CM[.app], by Portola Pharmaceuticals, a biopharmaceutical company with a foundation of products and product candidates that significantly advances patient care in the areas of thrombosis, other hematologic disorders and inflammation. Portola's legal and finance teams now use Corridor's software to manage their entire contract lifecycle, including contract creation and request, negotiation with external parties, documented approval, and metadata reporting.
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
GlobeNewswire - Wed Jun 01, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies. PTLA: 25.98 (+0.02)
Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Tue May 31, 3:05PM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that Bill Lis, chief executive officer, will present at the Goldman Sachs 37 Annual Healthcare Conference on Tuesday, June 7, 2016, at 1:20 p.m. Pacific Time in Rancho Palos Verdes, Calif. PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
GlobeNewswire - Fri May 27, 7:45AM CDT
--Company Plans to Submit NDA and MAA for Betrixaban in Second Half of 2016--
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa(TM) (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardization Committee Meeting
GlobeNewswire - Mon May 23, 7:00AM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA) today announced that the full data set from the Phase 3 APEX Study of betrixaban will be featured in an oral session at the 62nd Annual Scientific and Standardization Committee (SSC) Meeting of the International Society on Thrombosis and Haemostasis (ISTH), which will take place from May 25-28 in Montpellier, France. Additionally, new data from pharmacokinetic and mechanism of action studies of the Company's Factor Xa inhibitor antidote AndexXa (andexanet alfa) will be presented in poster sessions. PTLA: 25.98 (+0.02)
How are Investors Treating These Biotech? - Portola Pharma, Vitae Pharma, Anthera Pharma, and Intra-Cellular Therapies
PR Newswire - Thu May 19, 7:35AM CDT
There is no saying when exactly the Biotech space will fully recover given the relentless pressures in pricing and lack in consumer confidence. One thing is for sure in the investors circle though - numerous opportunities are up for grabs but this industry requires due-diligence. Ahead of today's session, ActiveWallSt.com's presents four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), and Intra-Cellular Therapies Inc. (NASDAQ: ITCI). Receive your complimentary alerts on these stocks by signing up today at:
PTLA: 25.98 (+0.02), ANTH: 3.08 (+0.02), VTAE: 10.65 (-0.40), ITCI: 40.80 (-0.17)
Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Thu May 05, 3:06PM CDT
Portola Pharmaceuticals Inc. (NASDAQ
TLA), today provided a corporate update and reported its financial results for the first quarter ended March 31, 2016. PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
GlobeNewswire - Thu Apr 14, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans. PTLA: 25.98 (+0.02)
3 Biotech Takeover Targets That Could Get Bought Soon
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 2:39PM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Biotech stocks have been especially hard hit over the past six months because of concerns over drug prices, and the sell-off within the industry has resulted in bargains that big pharma might find compelling. Among...
MDVN: 64.22 (+0.23), BMRN: 99.78 (+0.36), PTLA: 25.98 (+0.02), KITE: 57.00 (+0.37), AMGN: 172.20 (+0.17), BMY: 75.31 (+0.50)
What Made Portola Pharmaceuticals Shares Collapse 33% in March
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 4:02PM CDT
IMAGE SOURCE: PORTOLA PHARMACEUTICALS. What: After reporting confusing and arguably mixed results from a late-stage study, shares of Portola Pharmaceuticals lost roughly a third of their value last month, according to data from S&P...
PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis (ISTH) SSC Meeting 2016 on May 27, 2016
GlobeNewswire - Wed Apr 06, 7:07AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced that data from its Phase 3 APEX Study of betrixaban will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 62nd Annual SSC (Scientific and Standardization Committee) Meeting, which is taking place from May 25-28 in Montpellier, France. Portola is developing betrixaban, an oral Factor Xa inhibitor anticoagulant, for the prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients. PTLA: 25.98 (+0.02)
Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with Edoxaban in Japan
GlobeNewswire - Mon Apr 04, 7:00AM CDT
Portola Pharmaceuticals (NASDAQ
TLA), announced today that it has entered into a clinical collaboration agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban, Daiichi Sankyo's Factor Xa inhibitor, in Japan. PTLA: 25.98 (+0.02)
Portola Hits 52-Week Low on Unfavorable Betrixaban Data
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 10:30AM CDT
Shares of Portola (PTLA) hit a new 52-week low on unfavorable top-line data from the phase III APEX study on betrixaban.
PTLA: 25.98 (+0.02), EBS: 33.39 (+0.54), AMAG: 26.53 (-0.06), SNY: 42.63 (+0.03)
Portola Pharma and Williams skid, Office Depot and PVH climb
AP - Thu Mar 24, 3:51PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq stock market:
SPLS: 9.29 (+0.06), PTLA: 25.98 (+0.02), TEX: 24.14 (+0.59), ODP: 3.46 (-0.05), PVH: 101.06 (+1.44)
Why Portola Pharmaceuticals Inc's Stock Is Bleeding Red Today
Brian Feroldi, The Motley Fool - Motley Fool - Thu Mar 24, 12:12PM CDT
Image source: TBIT via Pixabay. What: Shares of Portola Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies for thrombosis and other hematologic diseases, dropped by more than 22% as of 11:00 a.m. EST...
PTLA: 25.98 (+0.02), SNY: 42.63 (+0.03)
Portola Pharmaceuticals' Betrixaban Misses Mark, But All Is Not Lost
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:14AM CDT
SOURCE: PORTOLA PHARMACEUTICALS Portola Pharmaceuticals ' 7,513 person head to head study evaluating its next-generation anticoagulant betrixaban against standard of care Lovenox in the prevention of blood clots missed its endpoint in one trial...
JNJ: 125.23 (+0.77), PTLA: 25.98 (+0.02), PFE: 37.04 (+0.15), BMY: 75.31 (+0.50), SNY: 42.63 (+0.03)
Portola Pharmaceuticals to Hold Conference Call on Thursday, March 24, at 8:30 am ET
GlobeNewswire - Thu Mar 24, 3:00AM CDT
Portola Pharmaceuticals, Inc. (Nasdaq
TLA) announced that it will host a conference call today, Thursday, March 24, 2016, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), to provide a company update. PTLA: 25.98 (+0.02)
3 Emerging Biotech Stocks I'm Watching Like a Hawk
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 19, 11:02AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM. Needle-moving news could soon hit for three small-cap biotech stocks. If investors aren't paying attention, they could miss out on an opportunity. Specifically, the FDA is set to decide whether to approve ...
INSY: 15.65 (+0.01), PTLA: 25.98 (+0.02), SHPG: 194.18 (+0.06), SNY: 42.63 (+0.03), FOLD: 6.72 (-0.08)
3 Biotech Stocks to Buy in March
Cheryl Swanson, Kristine Harjes, and Brian Feroldi, The Motley Fool - Motley Fool - Fri Mar 18, 3:39PM CDT
Looking for stocks to buy? It's time to get in some shots before the weather warms up. Flickr: Creative Commons March--as the saying goes--comes in like a lion and goes out like a lamb. And biotechs may be about to do the same, although it's...
PTLA: 25.98 (+0.02), IBB: 290.67 (+1.23), IONS: 38.15 (+8.96), REGN: 425.12 (+14.08)
